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To evaluate the efficacy and safety of capecitabine and cisplatin in patients with recurrent gastric cancer after fluoropyrimidine-based
adjuvant therapy. Patients with histologically confirmed and measurable advanced gastric cancer that had relapsed after
fluoropyrimidine-based adjuvant chemotherapy received oral capecitabine (1250mgm
 2 twice daily, days 1–14) and intravenous
cisplatin (60mgm
 2 over 1h, day 1) every 3 weeks. In total, 32 patients were enrolled, of whom 30 were evaluable for efficacy and
32 for safety. A median of 5 cycles (range 1–10) was administered. One patient achieved a complete response and eight had partial
responses, giving an overall response rate of 28% (95% CI, 13–44%). The median time to progression and median overall survival
were 5.8 months (95% CI, 4.1–7.5 months) and 11.2 months (95% CI, 5.5–16.9 months), respectively. Grade 3 neutropenia and
thrombocytopenia were observed in 38 and 6% of patients, respectively. Grade 2/3 nonhaematological toxicities included diarrhoea
(19%), stomatitis (19%) and hand-foot syndrome (31%). No grade 4 toxicity, neutropenic fever or treatment-related deaths
occurred. Capecitabine in combination with cisplatin was effective and well tolerated as first-line treatment in patients with recurrent
gastric cancer after fluoropyrimidine-based adjuvant chemotherapy.
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Gastric cancer is the second most common cancer worldwide
(Parkin et al, 1999). While the incidence of gastric cancer has been
declining for several decades, it varies substantially between
different racial and ethnic groups. For example, in South Korea,
gastric cancer remains the most common and most fatal malignant
neoplasm (Bae et al, 2002). Surgical resection is the only curative
treatment currently available for gastric cancer, but the role of
adjuvant chemotherapy after curative resection is unclear. A meta-
analysis showed that adjuvant chemotherapy was associated with
borderline statistically significant, but clinically insignificant,
survival improvement (Earle and Maroun, 1999). A more recent
meta-analysis (Janunger et al, 2002) of 21 randomised studies
found a significant survival benefit for patients treated with
postoperative adjuvant chemotherapy compared with controls
(odds ratio (OR) 0.84, 95% confidence interval (CI) 0.74–0.96).
However, when Western and Asian studies were analysed
separately there was no benefit in the Western groups (OR 0.96,
95% CI 0.83–1.12). Recently, the North American Intergroup
performed a prospective randomised study in 556 patients with
advanced oesophagogastric cancer receiving postoperative adju-
vant 5-FU/leucovorin plus radiotherapy (MacDonald et al, 2001).
In this study, chemoradiation led to a significant improvement in
median overall survival compared with surgery alone (36 vs 27
months, P¼0.005). However, this study has been criticised in light
of the poor overall survival, probably because inadequate surgery
(D0 lymph node dissection) was performed in over 50% of the
patients (Stahl, 2004). Overall, at the time of diagnosis, many
patients have locally advanced unresectable or metastatic disease
and, even after apparently complete resection, local and distant
relapses are common. The prognosis of patients with recurrent
gastric cancer is very poor, with the median duration of survival
ranging from 3 to 5 months in untreated patients (Glimelius et al,
1997).
In patients with unresectable/metastatic disease, first-line
chemotherapy is superior to best supportive care in terms of
quality of life and overall survival (Murad et al, 1993; Pyrhonen
et al, 1995; Glimelius et al, 1997). 5-FU is widely used for the
treatment of gastric cancer and other gastrointestinal tumours. 5-
FU in combination with cisplatin (FP regimen) is commonly used
in advanced disease because of the activity of both drugs when
administered as single agents. In randomised phase III trials in
advanced gastric cancer, FP led to improved response rates
compared with 5-FU, doxorubicin and mitomycin (FAM) or 5-FU
single-agent therapy (Kim et al, 1993), and showed a trend towards
improved response rates compared with 5-FU, doxorubicin and
methotrexate (FAMTX) or etoposide, leucovorin and bolus 5-FU
(ELF) (Vanhoefer et al, 2000). However, few studies have evaluated
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sthe efficacy of first-line treatment in patients with gastric cancer
that has relapsed after fluoropyrimidine-based adjuvant che-
motherapy. Furthermore, first-line chemotherapy after relapse is
often associated with pronounced adverse effects and response
rates rarely exceed 20% (Hill and Cunningham 1998). For these
reasons, novel compounds with activity and less toxicity are
needed in this setting.
The oral fluoropyrimidine capecitabine (Xeloda
s) was designed
to generate 5-FU preferentially in tumour tissue and to mimic a
continuous infusion of 5-FU while minimising systemic 5-FU
exposure. Following absorption, capecitabine is metabolised in a
three-step metabolic process, the final step being conversion to 5-
FU by thymidine phosphorylase (TP): tumour selectivity results
from the significantly greater TP activity in tumour tissue
compared with healthy tissue (Miwa et al, 1998; Schu ¨ller et al,
2000). In preclinical xenograft models, oral capecitabine has been
shown to be highly active against gastric cancer (Ishikawa et al,
1998; Ishitsuka, 2000). This finding was subsequently extended to
the clinic in a phase II study of previously untreated patients with
advanced gastric cancer, in which capecitabine 1250mgm
 2 twice
daily on days 1–14 every 3 weeks was both active (overall response
rate 28%; stable disease 36%) and well tolerated (Hong et al, 2004).
In addition, capecitabine showed activity in a preclinical xenograft
model of a 5-FU-resistant tumour (Cao et al, 1997) and some
activity in patients with metastatic colorectal cancer refractory to
5-FU/leucovorin chemotherapy (Lee et al, 2003).
As oral capecitabine is a highly active single agent and its safety
profile differs from that of cisplatin with little overlap of key
toxicities, capecitabine combined with cisplatin is an appealing
and convenient alternative to 5-FU/cisplatin. In a recent phase II
study (Kim et al, 2002), capecitabine plus cisplatin was active and
well tolerated as first-line chemotherapy. In the present phase II
study we evaluated the efficacy and safety of the same combination
regimen as first-line treatment in patients with gastric cancer
recurring after fluoropyrimidine-based adjuvant chemotherapy.
MATERIALS AND METHODS
Patient selection
Patients were considered eligible if they had histologically
confirmed advanced gastric cancer with at least one measurable
target lesion according to RECIST guidelines (Therasse et al, 2000)
(diameter of X2cm) that had relapsed after previous fluoropyr-
imidine-based adjuvant chemotherapy. In addition, patients had to
be 18–75 years old, have an Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2, have adequate liver, kidney,
and bone marrow function, and to have received no prior
treatment with capecitabine or platinum compounds. Patients
with unresolved bowel obstruction or malabsorption syndrome
were excluded. The protocol was approved by the institutional
review board of the Asan Medical Center, and all patients gave
written informed consent before enrolment.
Treatment schedule
Capecitabine was administered orally at a dose of 1250mgm
 2 twice
daily according to the standard intermittent schedule (14 days of
treatment followed by a 7-day rest period, every 3 weeks). Cisplatin
was administered intravenously on day 1 (before the first dose of
capecitabine) at a dose of 60mgm
 2 f o r1 hw i t hh y d r a t i o n ,a n d
repeated every 3 weeks. The hydration procedure consisted of 1l of
normal saline (containing 20mEq of KCl and 8mEq of MgSO4)
infused intravenously for 2.5h both before and after cisplatin
infusion, giving a total of 2l of saline infused over a 5-h period. In
addition, intravenous furosemide 20mg was given 30min before
infusing cisplatin. Mannitol was not used. A serotonin antagonist
and dexamethasone were routinely given before cisplatin adminis-
tration to prevent emesis. Treatment was given in the outpatient
clinic and continued until disease progression, unacceptable adverse
events, or withdrawal by the patient.
Evaluation of safety and dose modification
Safety was evaluated before each treatment cycle according to the
National Cancer Institute Common Toxicity Criteria (NCI-CTC),
version 2.0. To begin the next treatment cycle, each patient was
required to have a platelet count X75 10
9l
 1, a neutrophil count
X1 10
9l
 1 and resolution or improvement of clinically sig-
nificant nonhaematological adverse events (excluding alopecia) to
grade 1 or 0. Dose adjustments (interruption and/or reduction)
and discontinuation in response to adverse events were made for
each drug according to previous guidelines and depended on
classification, grade and frequency of occurrence (Kim et al, 2002).
Dose adjustment criteria for cisplatin were based on serum
creatinine levels immediately prior to each cycle: if serum
creatinine was o1.5mgdl
 1, full-dose cisplatin was given; if
serum creatinine was 1.5–2.5mgdl
 1, the cisplatin dose was
reduced by 50%; if serum creatinine was 42.5mgdl
 1, the patient
was excluded from the study. Patients were withdrawn from study
treatment (but still followed-up) if treatment was delayed for more
than 2 weeks.
Assessment of compliance and dose intensity
Compliance with capecitabine treatment was monitored by
questioning patients and counting their remaining pills at each
outpatient visit. The ratio of the actual administered dose to the
scheduled dose was then calculated. Dose intensity was defined as
the total amount of drug given (mgm
 2) divided by the number of
weeks.
Pretreatment, follow-up studies and response evaluation
Physical examination and chest X-rays were carried out before
each chemotherapy cycle, and complete blood counts and
biochemical tests were performed before and on day 15 of each
cycle. Response evaluation was performed by computed tomo-
graphy (CT) scan every 2–3 cycles until the tumour progressed.
Tumour response was classified on the basis of the response
evaluation criteria defined by RECIST guidelines (Therasse et al,
2000), and responses were required to last longer than 4 weeks.
Statistical analysis
All enrolled patients were included in the intention-to-treat (ITT)
analysis of efficacy. The trial was conducted according to the two-
stage Gehan design (Simon 1987) with response rate as the primary
end point. We planned to enrol at least 25 evaluable patients, with
a target minimum response rate of 20%. If no objective response
was seen among the first 14 patients in the study, the probability of
a response rate X20% would be o5%, and the study was to be
discontinued. One or more responses would indicate that
continuation was warranted, and at least 25 patients would be
required to estimate a response rate with a standard error of
approximately 10%. The number of patients enrolled was
increased to 32 patients to better estimate the response rate. The
Fisher’s exact test was used to compare late vs early relapse groups
and the different adjuvant regimens.
Time to progression (TTP), survival and duration of response
were secondary end points and were estimated using the Kaplan–
Meier method. The duration of response was defined as the
interval from the onset of complete response (CR) or partial
response (PR) until first evidence of disease progression. If death
occurred before progression was documented, the date of death
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swas assumed to be the date of progression. TTP was calculated
from the date of entry into the study until the date of progression,
and overall survival was measured from the date of entry to the
date of last follow-up or death.
RESULTS
Patient characteristics
A total of 32 patients were enrolled between October 2000 and
April 2003. Baseline characteristics, which are shown in Table 1,
show a relatively standard gastric cancer population (with more
males than females).
Efficacy and survival
A total of 30 patients were evaluable for response (Table 2). One
patient was not evaluable because of loss to follow-up after the first
cycle of treatment, and the second patient withdrew consent. One
CR and eight PRs were observed, giving an overall response rate of
28% (95% confidence intervals (CI), 13–44%) in the ITT analysis
(Table 2).
There was a numerically superior overall response rate in
patients whose tumour relapsed more than 6 months (late relapse
group) compared with those whose tumour relapsed within 6
months of completing adjuvant chemotherapy (early relapse
group) (39 vs 21%), although the difference did not reach
statistical significance (P¼0.427; Table 2). There was also no
significant difference in overall response rate in patients who
received doxifluridine7mitomycin-C (40%) compared with 5-
FUþdoxorubicinþmitomycin-C (23%, P¼0.407; Table 2).
The median duration of response in the nine responding
patients was 8.5 months (range 3.6–29.6 months). The median
follow-up period was 19.4 months (range 9.2–39.8 months). The
median TTP for all patients was 5.8 months (95% CI, 4.1–7.5
months; Figure 1). The median overall survival was 11.2 months
(95% CI, 5.5–16.9 months; Figure 2), with a 1-year survival rate of
49% (95% CI, 32–66%). Although there was a trend towards a
more prolonged overall survival (14.1 vs 9.3 months, P¼0.075)
and TTP (8.3 vs 5.4 months, P¼0.072) in the late relapse group
compared with the early relapse group, the differences did not
reach statistical significance.
Adverse events
A total of 173 treatment cycles (median 5; range 1–10 cycles) were
administered, of which there are no data for one cycle because one
Table 1 Patient characteristics
Characteristic No. %
Age (years)
Median 60
Range 38–73
Sex
Male 22 69
Female 10 31
ECOG performance status
01 3
13 0 9 4
21 3
Time between end of adjuvant chemotherapy and relapse
p6 months 19 59
46 months 13 41
Prior adjuvant chemotherapy
5-FU+doxorubicin+mitomycin-C 22 69
Doxifluridine7mitomycin-C 10 31
Metastatic sites
Liver 15 47
Abdominal lymph node 13 41
Peritoneum 6 14
Cervical lymph node 4 13
No. of metastases
12 1 6 6
X21 1 3 4
Table 2 Antitumour efficacy
Time from end of adjuvant therapy to relapse Prior adjuvant therapy
All patients
a (n¼32) 46 months (n¼13) p6 months (n¼19)
5-FU+doxorubicin+
mitomycin-C (n¼22)
Doxifluridine7
mitomycin-C (n¼10)
No. % No. % No. % No. % No. %
Complete response 1 3 1 8 0 0 0 0 1 10
Partial response 8 25 4 31 4 21 5 23 3 30
Stable disease 17 53 7 54 10 53 13 59 4 40
Progressive disease 4 13 1 8 3 16 2 9 2 20
Not evaluable 2 6 0 0 2 11 2 9 0 0
aIntention-to-treat analysis.
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Figure 1 Time to disease progression for all patients.
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spatient was lost to follow-up. The frequencies of treatment-related
haematological and nonhaematological adverse events are shown
in Table 3. The most common treatment-related haematological
adverse event was neutropenia, which occurred at grade 3 intensity
in 12 patients (38%). No patient experienced grade 4 neutropenia
or febrile neutropenia. Grade 2 hand-foot syndrome was also
relatively common, occurring in 10 patients (31%). There were no
treatment-related deaths.
Treatment interruption or dose reduction was required in 71
cycles. In total, 20 patients (62.5%) required dose reductions,
which were due to haematological adverse events (12 of 20
patients; 60%), hand-foot syndrome (three patients; 15%), nausea/
vomiting (two patients; 10%), stomatitis (one patient; 5%), and
diarrhoea (one patient; 5%). Treatment was delayed in 16 patients
(50%) as a result of haematological adverse events (13 patients;
81.3%), hand-foot syndrome (two patients; 12.5%), nausea/
vomiting (one patient; 6.3%) and stomatitis (one patient; 6.3%).
There was no treatment interruption or dose reduction with
cisplatin.
The median dose intensity for all treatment cycles was
8902mgm
 2week
 1 (range 4298–15576mgm
 2week
 1) for cape-
citabine and 19.2mgm
 2week
 1 (range 15.0–27.5mgm
 2week
 1)
for cisplatin, corresponding to 76 and 96%, respectively, of the
planned dose intensities. Although patient compliance with taking
their prescribed number of capecitabine tablets was good (97%
during the first six cycles), the dose intensity of capecitabine
decreased progressively during the first six cycles and fell below
80% of that planned after the second treatment cycle. Conversely,
the dose intensity of cisplatin was well maintained throughout the
first 6 cycles.
DISCUSSION
The present study suggests that the combination of capecitabine
and cisplatin is an effective and well-tolerated regimen for the first-
line treatment of patients with gastric cancer recurrent after
fluoropyrimidine-based adjuvant chemotherapy. This combination
regimen demonstrated promising efficacy, with a tumour response
rate of 28%, a median TTP of 5.8 months and a median overall
survival of 11.2 months. The efficacy demonstrated in the present
study may be a function of additive or synergistic antitumour
activity between the two agents also observed in other studies in a
variety of gastrointestinal cancers (Evans et al, 2002; Kim et al,
2002, 2003; Pivot et al, 2003). The lack of prior exposure to
cisplatin may have also played a role in the response to the
capecitabine–cisplatin combination.
It is difficult to compare the results of the present study with
other studies, as there is little information in the literature on
response to first-line chemotherapy after relapse of advanced
gastric cancer following fluoropyrimidine-based adjuvant che-
motherapy. The results of this study seem to be similar or
somewhat superior to those achieved with other regimens used in
this setting, such as weekly high-dose infusional 5-FU/leucovorin,
docetaxel or irinotecan (Futatsuki et al, 1994; Vanhoefer et al,
1994; Graziano et al, 2000; Giuliani et al, 2003). Weekly high-dose
infusional 5-FU/leucovorin has been reported to achieve a
response rate of 18% and a median overall survival of 5 months
(Vanhoefer et al, 1994), whereas docetaxel or irinotecan showed
objective response rates in the range of 5–27% and overall survival
times ranging from 3.5 to 10.2 months (Futatsuki et al, 1994;
Graziano et al, 2000; Giuliani et al, 2003). However, since our study
population was limited to patients with gastric cancer recurrent
after previous adjuvant chemotherapy, and excluded those with
metastatic advanced gastric cancer who failed first-line chemother-
apy, the results of this study should be interpreted cautiously.
Nevertheless, considering that single-agent cisplatin is associated
with a response rate of approximately 19% when used as first-line
therapy (Aabo et al, 1985; Perry et al, 1986), we would not have
expected to observe a response rate much greater than this by
combining a fluoropyrimidine (i.e. capecitabine) with cisplatin in
patients who had recurrent disease after prior fluoropyrimidine-
based adjuvant chemotherapy. Therefore, the current response rate
of 28% is encouraging.
The results of the present study are similar to our previous study
of the same regimen as a first-line treatment in previously
untreated patients with advanced gastric cancer (Kim et al, 2002)
with regard to both median overall survival (11.2 vs 10.1 months)
and median TTP (5.8 vs 6.3 months), although the objective
response rate was lower (28 vs 55%). It is logical that the same
chemotherapeutic regimen should have a lower response rate in
patients who have previously received fluoropyrimidine-based
adjuvant therapy than those who have not. The similar TTP and
overall survival may have been a result of differences in tumour
burden between the two study populations at the start of
chemotherapy; in the current study, 34% of patients had
involvement of more than one organ compared with 46% in our
previous study. In addition, these similar survival results may be
related to the second-line treatment received by patients; 47% of
patients received second-line treatment in the present study
compared with 29% of patients in our previous study. Also in
1.0
0.8
0.6
0.4
0.2
0.0
0 4 8 1 21 62 02 42 83 23 64 0
Time (months)
P
r
o
p
o
r
t
i
o
n
 
s
u
r
v
i
v
i
n
g
Figure 2 Overall survival for all patients.
Table 3 Most common treatment-related adverse events (410% of
patients)
Grade (% of patients)
a
1 2 3 4 All grades
Anaemia 31 50 16 0 97
Neutropenia 13 38 38 0 89
Hand-foot syndrome 50 31 0 0 81
Asthenia 34 44 0 0 78
Leukopenia 28 41 9 0 78
Nausea 28 47 0 0 75
Neuropathy 47 19 0 0 66
Thrombocytopenia 41 13 6 0 60
Diarrhoea 38 19 0 0 57
Constipation 19 31 0 0 50
Vomiting 19 28 0 0 47
Stomatitis 28 16 3 0 47
Hyperbilirubinaemia 13 6 0 0 19
Elevated transaminases 13 0 0 0 13
aNCI-CTC, version 2.0.
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sthe current study, patients with early relapse, who may have
developed fluoropyrimidine-resistant tumours, showed a favour-
able response rate, TTP and overall survival, suggesting that the
combination of capecitabine and cisplatin may overcome drug
resistance to fluoropyrimidines. However, further studies are
required to verify this observation.
Owing to the limited response duration, TTP and overall
survival in patients with gastric cancer, safety and tolerability are
important considerations in the assessment of new treatment
regimens. The combination of capecitabine and cisplatin has
previously shown good antitumour efficacy with a favourable
safety profile as first-line chemotherapy in advanced gastric (Kim
et al, 2002) and biliary cancer (Kim et al, 2003), and also as salvage
treatment in previously treated head and neck cancer patients
(Pivot et al, 2003). In the present study, adverse events were
generally mild and manageable without the need for hospitalisa-
tion. There were no treatment-related deaths or cases of febrile
neutropenia, despite 38% of patients developing grade 3 neutro-
penia. Hand-foot syndrome was common, but severe cases were
successfully prevented through strict adherence to a predefined
dose modification schedule. These data suggest that capecitabine
in combination with cisplatin can be administered safely in an
outpatient clinic setting.
Compliance with capecitabine, which is very important for oral
chemotherapeutic agents, was generally very good. However, the
median dose intensity for capecitabine was 76% of that planned
because of dose reductions or delays primarily associated with
neutropenia. In addition, the dose intensity of capecitabine
gradually decreased over the first six treatment cycles, just as in
other phase II studies of capecitabine plus cisplatin as first-line
chemotherapy (Kim et al, 2002, 2003). Therefore, we recommend
that the starting dose of capecitabine be reduced to 1000mgm
 2
twice daily on days 1–14 every 3 weeks in any future evaluations of
this combination.
It is interesting to note that triple-drug combinations, such as
ECF (Webb et al, 1997), have shown particularly favourable
responses in the first-line treatment of previously untreated
advanced gastric cancer. Recently, we conducted a phase I/II
study of a new triple-drug combination of docetaxel–capecita-
bine–cisplatin as first-line therapy in advanced gastric cancer and
observed very promising efficacy and acceptable safety (Kang et al,
2004). Capecitabine/cisplatin in combination with epirubicin
(ECX) is also being evaluated in a randomised phase III study
(REAL2 trial) as first-line therapy for previously untreated
advanced gastro-oesophageal cancer (Sumpter et al, 2003); another
triple combination including capecitabine (epirubicin/oxaliplatin/
capecitabine: EOX) is being examined in this trial together with the
complimentary regimens containing 5-FU (ECF and epirubicin/
oxaliplatin/5-FU: EOF). An international phase III trial is also
underway to evaluate replacing infusional 5-FU with capecitabine
in 5-FU/cisplatin combination chemotherapy in first-line advanced
gastric cancer.
In conclusion, the combination of capecitabine and cisplatin is
effective and well tolerated as a first-line treatment for gastric
cancer recurrent after prior fluoropyrimidine-based adjuvant
chemotherapy. It would be interesting to speculate that addition
of a third agent (e.g. epirubicin, docetaxel, paclitaxel, irinotecan)
to capecitabine/cisplatin might improve this response in recurrent
gastric cancer after prior fluoropyrimidine-based adjuvant che-
motherapy. With the increasing adoption of adjuvant chemother-
apy and chemoradiotherapy after surgery for advanced gastric
cancer, there will be an expansion of studies into the use of first-
line chemotherapy regimens for recurrence of gastric cancer
following prior adjuvant therapy.
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